NM_000162.5:c.523G>C
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PP4_ModeratePM2_SupportingPP2PP3PS1PS4PP1_Strong
This summary comes from the ClinGen Evidence Repository: The c.523G>C variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 175 (p.(Gly175Arg)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.965, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in five unrelated individuals with hyperglycemia (PS4_Moderate; PMIDs:21978167, internal lab contributors). This variant segregated with diabetes/hyperglycemia, with at least six informative meioses in two families (PP1_Strong; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%, antibody negative and three-generation, dominant family history of diabetes or hyperglycemia in a family not used for PP1) (PP4_Moderate; PMIDs:21978167). The nucleotide change c.523G>A, which causes the same amino acid change, has been classified as pathogenic for monogenic diabetes by the ClinGen MDEP (PS1). In summary, c.523G>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PP4_Moderate, PS4_Moderate, PM2_Supporting, PP2, PP3, PS1. LINK:https://erepo.genome.network/evrepo/ui/classification/CA367401686/MONDO:0015967/086
Frequency
Consequence
NM_000162.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Monogenic diabetes Pathogenic:1
The c.523G>C variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 175 (p.(Gly175Arg)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.965, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in five unrelated individuals with hyperglycemia (PS4_Moderate; PMIDs:21978167, internal lab contributors). This variant segregated with diabetes/hyperglycemia, with at least six informative meioses in two families (PP1_Strong; internal lab contributors). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%, antibody negative and three-generation, dominant family history of diabetes or hyperglycemia in a family not used for PP1) (PP4_Moderate; PMIDs:21978167). The nucleotide change c.523G>A, which causes the same amino acid change, has been classified as pathogenic for monogenic diabetes by the ClinGen MDEP (PS1). In summary, c.523G>C meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Strong, PP4_Moderate, PS4_Moderate, PM2_Supporting, PP2, PP3, PS1. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.